Dr. Kottler sat down with Diagnostic Imaging at RSNA 2023 to discuss AI imaging milestones and the potential impact of AI on workflows in radiology.
Artificial intelligence (AI) is of course one of, if not the hottest topic at this year's RSNA annual meeting, but how is all of the hype translating to clinical practice?
As exciting as new technology can be, actually using that technology requires a great deal of effort, especially for larger institutions that are faced with training dozens of radiology staff.
User education is a key component to adoption and uptake, according to Nina Kottler, MD, MS, associate chief medical officer of clinical artificial intelligence at Radiology Partners. Dr. Kottler spoke with Diagnostic Imaging at RSNA 2023, where she reflected on Radiology Partners hitting (and recently surpassing) an impressive milestone: utilizing clinical AI in more than 20 million patient exams. None of that would be possible without purposeful training programs to make sure that radiology end-users are comfortable with the new technology and understand the key benefits of use.
Dr. Kottler, who is also an associate fellow at Stanford University's Center for Artificial Intelligence in Medicine & Imaging (AIMI), also spoke about what she has observed in terms of the affect that AI is having on radiology workflows.
Watch the interview below for additional insights on AI.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.